Shopping Cart
- Remove All
Your shopping cart is currently empty
MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that targets Akt1 [IC50: 8 nM], Akt2 [IC50: 12 nM], and Akt3 [IC50: 65 nM]. Many breast cancer cell lines, PIK3CA mutants, and PTEN-losing cell lines are sensitive to MK-2206, which exhibits anti-cancer effects.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,140 | 1-2 weeks | |
| 50 mg | $2,785 | 1-2 weeks | |
| 100 mg | $3,520 | 1-2 weeks |
| Description | MK-2206 is an orally active, highly selective, metabotropic Akt inhibitor that targets Akt1 [IC50: 8 nM], Akt2 [IC50: 12 nM], and Akt3 [IC50: 65 nM]. Many breast cancer cell lines, PIK3CA mutants, and PTEN-losing cell lines are sensitive to MK-2206, which exhibits anti-cancer effects. |
| Targets&IC50 | Akt1:8 nM, Akt3:65 nM, Akt2:12 nM |
| Synonyms | MK-2206 Monohydrochloride |
| Molecular Weight | 443.94 |
| Formula | C25H22ClN5O |
| Cas No. | 1032349-77-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.